Earnings Releases·Nov 12, 2026, 4:07 PM ET

NeuroPace — Third Quarter 2026 Earnings Summary

Total revenue declined 1.1% year-over-year to $23.1 million, while RNS System revenue grew 1.4% to $22.9 million; GAAP net loss narrowed to $3.3 million from $4.9 million, and non-GAAP operating income turned positive at $0.4 million versus a $1.4 million loss previously.
Full-year 2026 guidance was lowered to $91–$92 million in revenue (previously $99.5–$101.5 million) and adjusted EBITDA guidance was widened to ($8.5)–($9.5) million (previously ($7.5)–($8.5) million), though non-GAAP operating expenses were reduced to $85–$86 million and gross margin guidance raised to 83.0–83.5%.
Q3 performance was impacted by isolated account-level issues and field organization changes, with management expecting fourth-quarter scheduled cases to recover as these disruptions subside.
Strategic pipeline progress includes a submitted PMA-Supplement for Remote Care (180-day review), an expected year-end amendment for the idiopathic generalized epilepsy indication, and enrollment initiation for the AURORA adolescent study with data collection due in early 2027.